While financial markets across the globe are tumbling on concerns that the rapidly spreading coronavirus will inflict more damage on the global economy than previously anticipated, a few “coronavirus ...
Hosted on MSN
CODX stock nearly doubled in early trade – Co-Diagnostics’ Ebola strategy gets retail betting big
・Co-Diagnostics develops molecular diagnostic tests using its proprietary Polymerase Chain Reaction technology platform. ・According to a Reuters report, the recent Ebola outbreak has already resulted ...
Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Co-Diagnostics ( (CODX)) has shared an ...
Co-Diagnostics stock is up an impressive 86% to trade at $5.41 -- the best stock on the Nasdaq today -- after it was reported the company's CoPrimer technology is being used in a research project for ...
CoDiagnostics CODX recently announced that the Australian Patent Office has granted a patent covering its new Co-Dx PCR platform, marking the first patent issued for this point-of-care technology.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results